Maiuthed Arnatchai, Chantarawong Wipa, Chanvorachote Pithi
Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
Cell-based Drug and Health Products Development Research Unit, Chulalongkorn University, Bangkok, Thailand.
Anticancer Res. 2018 Jul;38(7):3797-3809. doi: 10.21873/anticanres.12663.
The novel information regarding molecular and translational research have created a paradigm shift in the understanding of lung cancer biology, revealing the more precise target for anti-cancer drug discovery. Lung cancer is a leading cause of cancer death worldwide accounting for approximately 1 in 5 of all cancer-related deaths. The most important causes of death in such a cancer involves the treatment failure as well as the spreading of cancer cells to distant sites which the cancer stem cell (CSC) within the tumor is accepted as a key driver. CSC is a rare special population of cancer cells exhibiting high tumorigenic properties together with self-renewal and differentiation capability. CSC is not only linked with high tumor-initiating activity, but is also implicated in chemotherapeutic resistance, metastasis, epithelial to mesenchymal transition, and recurrence. Thereafter, novel therapeutic strategies targeting these CSCs are considered in order to improve long-term clinical outcome. Here, we provide sufficient data regarding the biology of CSC in lung cancer, known CSC markers and cellular signals, and promising compounds targeting the stem cell signals in lung cancer that may benefit the development of novel anti-cancer treatment.
有关分子和转化研究的新信息在肺癌生物学的理解上引发了范式转变，揭示了抗癌药物发现的更精确靶点。肺癌是全球癌症死亡的主要原因，约占所有癌症相关死亡的五分之一。这种癌症最重要的死亡原因包括治疗失败以及癌细胞扩散到远处部位，肿瘤内的癌症干细胞（CSC）被认为是关键驱动因素。CSC是一种罕见的特殊癌细胞群体，具有高致瘤性以及自我更新和分化能力。CSC不仅与高肿瘤起始活性相关，还与化疗耐药、转移、上皮-间质转化和复发有关。此后，考虑针对这些CSC的新型治疗策略以改善长期临床结果。在此，我们提供了有关肺癌中CSC生物学、已知CSC标志物和细胞信号以及靶向肺癌干细胞信号的有前景化合物的充分数据，这些可能有益于新型抗癌治疗的发展。
